The expanding biologics CDMO market: Innovative modalities and the role of NorthX Biologics
The pharmaceutical industry is experiencing a rapid transformation as advanced biologics – viral vectors, recombinant proteins, plasmid DNA, and cell and gene therapies – take center stage. With over 14,800 ...
Protein science and the future of biotherapeutics
The study of proteins is transforming our understanding of human biology and disease, enabling breakthroughs in diagnostics, drug development, and advanced therapies. In this article, Mathias Uhlén, Professor of Microbiology ...
Navigating the complexities of microbial and mammalian manufacturing
With a rich historical legacy and decades of expertise at its two sites, NorthX Biologics has long mastered the complexities of microbial and mammalian manufacturing. By offering capabilities and differentiating ...
Advancing the science of technical and therapeutic proteins
The life sciences and healthcare ecosystem relies on a diverse range of chemical modalities, with technical proteins playing a critical role in enabling the production and purification of therapeutic proteins ...
Sweden as a pharmaceutical manufacturing country
Based on a blog post by NorthX Biologics’ CEO Janet Hoogstraate at Stockholm Science City Foundation Sweden holds a unique position in life sciences and has, for decades, been a leading ...
The Nordics are dancing on
What’s hot and what’s not in ATMP? Insights from service providers, investors, and academics at the 2024 BIO-Europe conference in Stockholm. BIO-Europe celebrated its 30th anniversary in Stockholm, Sweden, on ...
Overcoming challenges and embracing innovation in biopharmaceutical manufacturing
The article is based on a podcast and interview with Janet Hoogstraate in March 2025. The biopharmaceutical industry is evolving rapidly, and innovation in manufacturing is playing a crucial role ...
X marks the spot
Discover a rich history of GMP manufacture, CMC experience and regulatory expertise. NorthX Biologics offers a comprehensive spectrum of biologics, including recombinant proteins, virus products, extracellular vesicles, and an array ...
Podcast with investor Ted Fjällman
NorthX Biologics’ investor and CEO of Flerie, Ted Fjällman made a guest appearance in a recent episode of Värdeskaparna, a podcast taking the audience behind the scenes in the private ...